IFPI-2026 in Hanoi will unite Regulators and Leading Pharmaceutical Manufacturers

The III International Forum of Pharmaceutical Inspectorates (IFPI 2026) will traditionally serve as a platform for professional dialogue between regulatory authorities and the business community, while its partnership programme confirms the industry’s strong interest in the Forum.

The General Sponsor of IFPI 2026 is Danapha Pharmaceutical JSC, part of the Danson-BG International Pharmaceutical Holding. Partnership at this level highlights the company’s commitment to improving the quality and safety of medicinal products, as well as its role in strengthening dialogue between business and regulators.

The Forum is also supported by other leading representatives of the pharmaceutical industry, reflecting the market’s shared interest in developing a quality culture and harmonising GMP standards. Among them are:

• PRO.MED.CS
• Geropharm
• Pharmasyntez
• Fortis Medica
• R-Pharm
• AstraZeneca
• Skopinpharm
• Servier
• Petrovax
• Promomed
• Rhana
• Competence Centre

In addition, a specialised exhibition will take place as part of the Forum, featuring exhibiting companies. The following companies will present their stands at the venue:

• Danapha Pharmaceutical JSC
• Vetprom AD
• Danson International Pharmaceutical Holding
• R-Pharm
• AstraZeneca
• Geropharm
• Pharmasyntez
• Competence Centre
• PRO.MED.CS

The exhibition serves as a practical platform for experience exchange, technology transfer and entering new foreign markets. In 2025, leading pharmaceutical companies already showcased innovative medicinal products, biosimilars and generics at this venue. In 2026, the exhibition area will be expanded with thematic sessions on advanced therapy medicinal products (ATMPs), radiopharmaceuticals and blood products.